PDF herunterladen
Endoscopy 2000; 32(5): 411-418
DOI: 10.1055/s-2000-8998
ESGE Opinion Paper
Georg Thieme Verlag Stuttgart · New York

The Second European Endoscopy Forum (Sintra, Portugal, 17 - 18 June 1999): Twenty Questions on the Esophagogastric Junction

A. Axon 1 , R. Lambert 2 , M. Robaszkiewicz 3 , T. Rösch 4 , A. Sonnenberg 5
  • 1 Division of Gastroenterology, The General Infirmary, Leeds, United Kingdom
  • 2 Department of Digestive Diseases, Hospital E. Herriot, Lyon, France
  • 3 Department of Gastroenterology, CHU de la Cavale Blanche, Brest, France
  • 4 Department of Internal Medicine II, Technical University of Munich, Germany
  • 5 Department of Radiology, The University of Texas Medical Branch, Galveston, Texas, USA
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Introduction

The purpose of the Second European Endoscopy Forum was to agree on definitions and to discuss the pathogenesis of Barrett's esophagus (BE) and associated adenocarcinoma. It was agreed that the term “Barrett's esophagus” was a good one, since although our current concepts of this condition do not necessarily coincide with those originally described by Barrett, the use of the term is generally understood, and it is concise. The Symposium generally focused on the diagnosis and endoscopic management of BE, as well as on cost-effectiveness aspects.

References

  • 1 Barrett NR. The lower oesophagus lined by columnar epithelium.  Surgery. 1957;  41 881-894
    PubMedGoogle Scholar
  • 2 Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined Barrett's esophagus: comparison of population based clinical and autopsy findings.  Gastroenterology. 1990;  99 918-922
    PubMedGoogle Scholar
  • 3 Chalsani N, Woo JM, Hunter JG, Waring SP. Significance of intestinal metaplasia in different areas of the oesophagus including oesophagogastric junction.  Dig Dis Sci. 1997;  42 603-607
    CrossrefPubMedGoogle Scholar
  • 4 Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.  Gastroenterology. 1999;  116 277-285
    CrossrefPubMedGoogle Scholar
  • 5 Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus: functional assessment, proposed pathogenesis, and surgical therapy.  Arch Surg. 1983;  118 543-549
    PubMedGoogle Scholar
  • 6 Kahrilas PJ. Anatomy and physiology of the gastroesophageal junction.  Gastroenterol Clin North Am. 1997;  3 467-485
    PubMedGoogle Scholar
  • 7 Levine DS. Management of dysplasia in the columnar-lined esophagus.  Gastroenterol Clin North Am. 1997;  3 613-634
    PubMedGoogle Scholar
  • 8 Ormsby AH, Goldblum JR, Richter JE, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.  Hum Pathol. 1999;  30 288-294
    CrossrefPubMedGoogle Scholar
  • 9 Spechler SJ. The columnar-lined esophagus: histology, terminology and clinical issues.  Gastroenterol Clin North Am. 1997;  26 445-466
    PubMedGoogle Scholar
  • 10 Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction.  Gastroenterology. 1999;  117 218-228
    PubMedGoogle Scholar
  • 11 Spechler SJ, Goyal RK. Barrett's esophagus.  N Engl J Med. 1986;  315 362-371
    PubMedGoogle Scholar
  • 12 Van der Burgh A, Dees J, Hopp WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.  Gut. 1996;  39 5-8
    PubMedGoogle Scholar
  • 13 Wijnhoven BP, Siersema PD, Hop WC, et al. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity (Rotterdam Oesophageal Tumour Group).  Br J Surg. 1999;  86 529-535
    CrossrefPubMedGoogle Scholar
  • 14 Wright TA. High-grade dysplasia in Barrett's oesophagus.  Br J Surg. 1997;  84 760-766
    CrossrefPubMedGoogle Scholar
  • 15 Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.  Am J Gastroenterol. 1999;  94 86-91
    CrossrefPubMedGoogle Scholar
  • 16 Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.  Cancer. 1998;  83 2049-2053
    CrossrefPubMedGoogle Scholar
  • 17 Dolan K, Sutton R, Walker SJ, et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology.  Br J Cancer. 1999;  80 834-842
    CrossrefPubMedGoogle Scholar
  • 18 Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway, 1958 - 1992: incidence, time trend variability according to morphological subtypes and organ subsites.  Int J Cancer. 1997;  71 340-344
    CrossrefPubMedGoogle Scholar
  • 19 National Cancer  Institute. Surveillance, Epidemiology, and End Results. SEER*Stat for Windows 95/NT, Version 1.1: SEER cancer incidence public-use database, 1993 - 1995.  Bethesda, MD; US Department of Health and Human Services, 1997
  • 20 Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus.  Gastroenterology. 1994;  107 747-754
    PubMedGoogle Scholar
  • 21 Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease.  Gastroenterology. 1990;  98 654-661
    PubMedGoogle Scholar
  • 22 Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus.  Am J Gastroenterol. 1997;  92 27-31
    PubMedGoogle Scholar
  • 23 El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease.  Gut. 1998;  43 333
    PubMedGoogle Scholar
  • 24 El-Serag HB, Sonnenberg A. Associations among different forms of gastroesophageal reflux disease.  Gut. 1997;  41 594-599
    PubMedGoogle Scholar
  • 25 Galmiche JP, Janssens J. The pathophysiology of gastro-oesophageal reflux disease: an overview.  Scand J Gastroenterol. 1995;  30 (Suppl 211) 7-18
    PubMedGoogle Scholar
  • 26 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.  N Engl J Med. 1999;  340 825-831
    CrossrefPubMedGoogle Scholar
  • 27 Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors.  Am J Dig Dis. 1976;  21 953-956
    CrossrefPubMedGoogle Scholar
  • 28 Sonnenberg A, El-Serag HB. Epidemiology of gastroesophageal reflux disease. In: Büchler MW, Farthmann EH Progress in Surgery, vol. 23. Basle; Karger 1997: 36
    Google Scholar
  • 29 Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study.  Gastroenterology. 1992;  102 1259-1268
    PubMedGoogle Scholar
  • 30 Burtin P, Napoleon B, Palazzo L, et al. Interobserver agreement in endoscopic ultrasonography staging of esophageal and cardia cancer.  Gastrointest Endosc. 1996;  43 20-24
    PubMedGoogle Scholar
  • 31 Canto M. Vital staining and Barrett's esophagus.  Gastrointest Endosc. 1999;  49 6
    PubMedGoogle Scholar
  • 32 Eloubeidi MA, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy.  Am J Gastroenterol. 1999;  94 937-943
    CrossrefPubMedGoogle Scholar
  • 33 Ellis KK, Oehlke M, Helfand M, Lieberman D. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management?.  Am J Gastroenterol. 1997;  92 1472-1474
    PubMedGoogle Scholar
  • 34 Ellis FH, Loda M. Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett' s adenocarcinoma.  Dis Esophagus. 1997;  10 165-171
    PubMedGoogle Scholar
  • 35 Murata Y. The role of endoscopic ultrasonography for gastric cancer in the cardiac area [in Japanese].  Nippon Geka Gakkai Zasshi. 1998;  99 564-568
    PubMedGoogle Scholar
  • 36 Tytgat GN. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any value?.  Endoscopy. 1995;  27 19-26
    PubMedGoogle Scholar
  • 37 Tytgat GN. Endoscopic features of the columnar-lined esophagus.  Gastroenterol Clin North Am. 1997;  3 507-517
    PubMedGoogle Scholar
  • 38 Fennerty MB. Perspectives on endoscopic eradication of Barrett's esophagus: who are appropriate candidates and what is the best method?.  Gastrointest Endosc. 1999;  49 (3) 24-28
    PubMedGoogle Scholar
  • 39 Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid.  Gastroenterology. 1998;  114 448-455
    PubMedGoogle Scholar
  • 40 Lightdale CJ. Ablation therapy for Barrett's esophagus: is it time to choose our weapons?.  Gastrointest Endosc. 1999;  49 122-125
    PubMedGoogle Scholar
  • 41 Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.  Gastrointest Endosc. 1999;  49 1-7
    CrossrefPubMedGoogle Scholar
  • 42 Van den Boogert J, van Hillegersberg R, Siersema PD, et al. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review.  Am J Gastroenterol. 1999;  94 1153-1160
    PubMedGoogle Scholar
  • 43 Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid-term results.  Gut. 1998;  43 747-751
    PubMedGoogle Scholar
  • 44 Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus.  Am J Gastroenterol. 1994;  89 670-680
    PubMedGoogle Scholar
  • 45 Sonnenberg A. Esophageal diseases. In: Everhart JE Digestive diseases in the United States: epidemiology and impact (US Department of Health and Human Services, NIH publication no. 94-1447). Washington, DC; US Government Printing Office 1994: 356
    Google Scholar
  • 46 Sonnenberg A, El-Serag HB. Economic aspects of endoscopic screening for intestinal precancerous conditions.  Gastrointest Endosc Clin North Am. 1997;  7 165-184
    PubMedGoogle Scholar
  • 47 Sonnenberg A, Delco F, El-Serag HB. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis.  Dig Dis Sci. 1998;  43 1001-1008
    CrossrefPubMedGoogle Scholar
  • 48 Wright TA, Gray MR, Morris AI, et al. Cost-effectiveness of detecting Barrett's cancer.  Gut. 1996;  39 574-579
    CrossrefPubMedGoogle Scholar

M.D. R. Lambert

International Agency for Research on Cancer

150, Cours A. Thomas

Lyon 69003

France

Telefon: +33-4-72110147

eMail: lambert@iarc. fr